RASILEZ 150 mg. 28 tablets

NOVARTIS
RASILEZ 150 mg. 28 tablets
€ 44.00
Add to Cart
The recommended dose of Rasilez is 150 mg once daily. In patients whose blood pressure is not adequately controlled, the dose may be increased to 300 mg once daily.
The antihypertensive effect occurs within two weeks after starting treatment with a dose of 150 mg once daily.

RASILEZ table. 150 mg. 28 table
 

Qualitative and quantitative composition:

Each tablet contains 150 mg aliskiren.
 

Indications

 
Treatment of essential hypertension.
 
Dosage and administration:
 
The recommended dose of Rasilez is 150 mg once daily. In patients whose blood pressure is not adequately controlled, the dose may be increased to 300 mg once daily.
The antihypertensive effect occurs within two weeks after starting treatment with a dose of 150 mg once daily.
Rasilez may be used alone or in combination with other antihypertensive agents.
It should be taken once daily with a light meal, preferably at the same vreem every day. It should not be taken with grapefruit juice.
 
Renal impairment:
 
No adjustment of the initial dose pratsietni with mild to severe renal impairment
 
Hepatic impairment:
 
No adjustment of the starting dose in patients with mild to severe hepatic impairment
 
Elderly:
 
No adjustment of the initial dose in the elderly.
 
Paediatric / under 18 /
 
Not recommended the use of Rasilez in children and adolescents below 18 years due to insufficient data on safety and efficacy.
 

Contraindications:

 
Hypersensitivity to the active substance or to any of the excipients. History of angioedema with aliksiren. Hereditary or idiopathic angioedema. Second and third trimesters of pregnancy. Concomitant use of aliskiren with cyclosporine or itraconazole, two highly potent - P-gp, or other potent inhibitors of P-gp is contraindicated.
 

Special warnings and precautions for use:

 
Patients taking other drugs that inhibit the renin-angiotensin system and / or those with reduced renal function and / or diabetes mellitus are at increased risk of hyperkalemia during treatment with aliskiren.
Aliskiren should be used with caution in patients with severe congestive heart failure functional class III-IV by NYHA.
If severe or persistent diarrhea Rosilez intake should be stopped.
 
Angioedema
 
As with other agents acting on the renin-angiotensin system in patients treated with aliskiren reported cases of angioedema or symptoms suggestive of angioedema.
A subset of these patients there is a history of angioedema or symptoms suggestive of angioedema due in some cases the use of other drugs capable of inducing angioedema, including RAS inhibitors or angiotensin receptor blockers.
 
Patients with a history of angioedema may be at increased risk of angioedema during treatment with aliskiren. Caution should be exercised when prescribing aliskiren in patients with a history of angioedema, and such patients should be carefully monitored during treatment and especially at the initiation of treatment.
 
If angioedema need immediate discontinuation of Rasilez, conducting appropriate therapy and monitoring provided until complete and sustained resolution of signs and symptoms.
 

Sodium and / or volume-depleted

 
Patients with marked volume-and / or salt-depletion can occur symptomatic hypotension following initiation of treatment with Rasilez. This condition should be corrected prior to administration of Rasilez, or the treatment should start under close observation medicine.
 

Renal impairment

 
As with other agents acting on the renin-angiotensin system, caution should be exercised when aliskiren in the presence of predisposing to kidney failure fektori such as hypovolemia, heart disease, liver disease or kidney disease. During post-marketing experience, cases of acute renal failure, reversible upon discontinuation of treatment in at-risk patients receiving aliskiren.
In the event of any signs of renal failure occur, aliskiren should be discontinued immediately.
 

Renal artery stenosis

 
No controlled clinical data on the use of Rasilez in patients with unilateral or bilateral renal artery stenosis or stenosis to a solitary kidney. Toda However, as with other agents acting on the renin-angiotensin system, there is an increased risk of renal insufficiency, including acute renal failure in patients with renal artery stenosis treated with aliskiren. Therefore, in these patients, caution is required. If renal failure occurs, treatment should be discontinued
 

Adverse reactions

 
Metabolism and nutrition disorders:
Uncommon - hyperkalemia
 
Gastrointestinal disorders:
Common - Diarrhea
 
Skin and subcutaneous tissue disorders:
Uncommon - rash
Rare - angioedema
 
Renal and urinary disorders:
Uncommon - acute renal failure, renal impairment
 
General disorders and administration site conditions:
Uncommon - peripheral edema
 
Investigations
Rare - Reduction in hemoglobin, decrease in hematocrit
Rare - Increase in serum creatinine.
€ 44.00
Add to Cart
Close